GlassScriptPhysician profile
Maria S Posadas
NPI 1457362113
$23,502.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $76.31 · 2021: $14.49 · 2022: $488.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13,119.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $7,818.27 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,480.14 | 2019-2020 | |
| Lilly USA, LLC | $487.50 | 2022 | |
| Mannkind Corporation | $262.35 | 2019 | |
| Amgen INC. | $126.95 | 2019 | |
| Corcept Therapeutics | $74.73 | 2019-2020 | |
| Abbvie INC. | $55.71 | 2019-2020 | |
| Radius Health, INC. | $27.89 | 2019-2021 | |
| Abbott Laboratories | $19.65 | 2019 | |
| Medtronic Minimed, INC. | $17.40 | 2019 | |
| Pfizer INC. | $13.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Posadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.